Author | Stéphanie Gaillard, MD, PhD

Articles

Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer: Many Questions, Much Promise…

February 21, 2011

In 2006, after a third consecutive large-scale US phase III trial conducted by the Gynecologic Oncology Group (GOG) confirmed that use of intraperitoneal (IP) chemotherapy in optimally resected stage III epithelial ovarian cancer results in superior overall survival (OS) and/or progression-free survival (PFS),[